NZ335853A - Method of using COX-2 inhibitors as anti-angiogenic agents - Google Patents

Method of using COX-2 inhibitors as anti-angiogenic agents

Info

Publication number: NZ335853A
Authority: NZ; New Zealand
Prior art keywords: benzenesulfonamide; alkyl; phenyl; trifluoromethyl; pyrazol
Prior art date: 1996-11-19

Application number

NZ335853A

Other languages

English (en)

Inventor

Jaime L Masferrer

Amiram Raz

Original Assignee

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-19

Filing date

1997-11-19

Publication date

2002-02-01

1997-11-19 Application filed by G filed Critical G

2002-02-01 Publication of NZ335853A publication Critical patent/NZ335853A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pyridine Compounds (AREA)

NZ335853A 1996-11-19 1997-11-19 Method of using COX-2 inhibitors as anti-angiogenic agents NZ335853A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3140496P	1996-11-19	1996-11-19
PCT/US1997/021489 WO1998022101A2 (en)	1996-11-19	1997-11-19	Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents

Publications (1)

Publication Number	Publication Date
NZ335853A true NZ335853A (en)	2002-02-01

Family

ID=21859277

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ335853A NZ335853A (en)	1996-11-19	1997-11-19	Method of using COX-2 inhibitors as anti-angiogenic agents

Country Status (19)

Country	Link
EP (1)	EP0941080A2 (ro)
JP (1)	JP2001505564A (ro)
KR (1)	KR20000053362A (ro)
CN (1)	CN1247470A (ro)
AU (1)	AU730211B2 (ro)
BR (1)	BR9713522A (ro)
CA (1)	CA2270469C (ro)
CZ (1)	CZ176899A3 (ro)
ID (1)	ID21979A (ro)
IL (1)	IL129604A (ro)
NO (1)	NO992309D0 (ro)
NZ (1)	NZ335853A (ro)
PL (2)	PL194717B1 (ro)
RO (1)	RO118566B1 (ro)
RU (1)	RU2268716C2 (ro)
SK (1)	SK59999A3 (ro)
TR (1)	TR199901703T2 (ro)
UA (1)	UA70294C2 (ro)
WO (1)	WO1998022101A2 (ro)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6512121B2 (en)	1998-09-14	2003-01-28	G.D. Searle & Co.	Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6515014B2 (en)	1995-06-02	2003-02-04	G. D. Searle & Co.	Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6887893B1 (en)	1997-12-24	2005-05-03	Sankyo Company, Limited	Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030013739A1 (en) *	1998-12-23	2003-01-16	Pharmacia Corporation	Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
KR20010109275A (ko) *	1998-12-23	2001-12-08	로저 에이. 윌리암스	종양치료의 병용치료로서 사이클로옥시게나제-2 억제제와기질 금속단백분해효소 억제제를 사용하는 방법
EP1637137A3 (en) *	1999-03-10	2006-07-05	G.D. Searle LLC	Method and composition for administering a cyclooxygenase-2 inhibitor to animals
ATE294574T1 (de) *	1999-07-29	2005-05-15	Tularik Inc	Kombination therapie mit pentafluorobenzenesulfonamid und platin-derivate
WO2001087287A2 (en)	2000-05-19	2001-11-22	Applied Research Systems Ars Holding N.V.	Use of pyrazole derivatives for treating infertility
AU2002234165A1 (en)	2000-11-03	2002-05-27	Tularik, Inc.	Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
KR100686537B1 (ko) *	2001-12-28	2007-02-27	씨제이 주식회사	사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
JP2006503812A (ja) *	2002-07-17	2006-02-02	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	アロステリックカルボキシルマトリックスメタロプロテイナーゼ−１３阻害薬とセレコキシブまたはバルデコキシブではない選択的シクロオキシゲナーゼ−２阻害薬との組み合わせ
KR100484525B1 (ko) *	2002-10-15	2005-04-20	씨제이 주식회사	이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
AT504159A1 (de) *	2006-08-16	2008-03-15	Marlyn Nutraceuticals Inc	Verwendung von proteasen
RU2475257C1 (ru) *	2011-06-22	2013-02-20	Людмила Николаевна Третьяк	Средство для повышения адаптируемости организма к экстремальным условиям
GB2496135B (en) *	2011-11-01	2015-03-18	Valirx Plc	Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE9422447U1 (de) *	1993-01-15	2002-10-17	G.D. Searle LLC, Chicago, Ill.	3,4-Diarylthiophene und Analoga davon, sowie deren Verwendung als entzündungshemmende Mittel
US5436265A (en) *	1993-11-12	1995-07-25	Merck Frosst Canada, Inc.	1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
NZ276885A (en) *	1993-11-30	1999-08-30	Searle & Co	Substituted pyrazolyl-benzenesulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5521213A (en) *	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
DE69529690T2 (de) *	1994-12-21	2003-11-13	Merck Frosst Canada & Co., Halifax	Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
US5691374A (en) *	1995-05-18	1997-11-25	Merck Frosst Canada Inc.	Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

1997
- 1997-11-19 UA UA99063447A patent/UA70294C2/uk unknown
- 1997-11-19 BR BR9713522A patent/BR9713522A/pt not_active Application Discontinuation
- 1997-11-19 EP EP97949579A patent/EP0941080A2/en not_active Withdrawn
- 1997-11-19 AU AU72982/98A patent/AU730211B2/en not_active Ceased
- 1997-11-19 CN CN97181368A patent/CN1247470A/zh active Pending
- 1997-11-19 JP JP52396098A patent/JP2001505564A/ja not_active Withdrawn
- 1997-11-19 WO PCT/US1997/021489 patent/WO1998022101A2/en not_active Application Discontinuation
- 1997-11-19 SK SK599-99A patent/SK59999A3/sk unknown
- 1997-11-19 CA CA002270469A patent/CA2270469C/en not_active Expired - Fee Related
- 1997-11-19 TR TR1999/01703T patent/TR199901703T2/xx unknown
- 1997-11-19 RO RO99-00572A patent/RO118566B1/ro unknown
- 1997-11-19 NZ NZ335853A patent/NZ335853A/en not_active Application Discontinuation
- 1997-11-19 IL IL12960497A patent/IL129604A/en not_active IP Right Cessation
- 1997-11-19 ID IDW990379A patent/ID21979A/id unknown
- 1997-11-19 CZ CZ991768A patent/CZ176899A3/cs unknown
- 1997-11-19 KR KR1019990704392A patent/KR20000053362A/ko not_active Application Discontinuation
- 1997-11-19 PL PL97373973A patent/PL194717B1/pl unknown
- 1997-11-19 RU RU99112952/14A patent/RU2268716C2/ru not_active IP Right Cessation
1999
- 1999-04-30 PL PL333370A patent/PL191793B1/pl unknown
- 1999-05-12 NO NO992309A patent/NO992309D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
RU2268716C2 (ru)	2006-01-27
KR20000053362A (ko)	2000-08-25
RO118566B1 (ro)	2003-07-30
NO992309L (no)	1999-05-12
TR199901703T2 (xx)	2000-07-21
CZ176899A3 (cs)	1999-10-13
PL333370A1 (en)	1999-12-06
PL194717B1 (pl)	2007-06-29
SK59999A3 (en)	2000-01-18
NO992309D0 (no)	1999-05-12
EP0941080A2 (en)	1999-09-15
CA2270469C (en)	2007-04-10
UA70294C2 (en)	2004-10-15
BR9713522A (pt)	2000-03-21
WO1998022101A3 (en)	1998-06-25
AU730211B2 (en)	2001-03-01
PL191793B1 (pl)	2006-07-31
WO1998022101A2 (en)	1998-05-28
ID21979A (id)	1999-08-19
CN1247470A (zh)	2000-03-15
IL129604A0 (en)	2000-02-29
AU7298298A (en)	1998-06-10
JP2001505564A (ja)	2001-04-24
IL129604A (en)	2004-08-31
CA2270469A1 (en)	1998-05-28

Publication	Publication Date	Title
US6025353A (en)	2000-02-15	Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
AU742645B2 (en)	2002-01-10	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US5972986A (en)	1999-10-26	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
WO1998016227A9 (en)	1998-07-30	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
CA2270469C (en)	2007-04-10	Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
CA2372912C (en)	2008-12-02	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
IL154502A (en)	2004-09-27	Use of cyclooxygenase-2 inhibitors in the preparation of medicaments for treating angiogenesis-related disorders
NZ517374A (en)	2003-10-31	Method of using cycloozygenase-2 inhibitors to prevent a neoplasia that produces a prostaglandin

Legal Events

Date	Code	Title
2001-10-26	AVOD	Application void
2002-05-31	PSEA	Patent sealed
2002-06-28	RENW	Renewal (renewal fees accepted)
2004-10-29	RENW	Renewal (renewal fees accepted)
2007-10-26	RENW	Renewal (renewal fees accepted)